Abstract
Monoclonal antibody 9.2.27 (mAb 9.2.27) directed to a chondroitin sulfate proteoglycan on human melanoma cells was able to suppress tumor growth in athymic (nu/nu) mice more effectively when bound with polyethylene glycol to murine effector cells than when injected alone. These "armed" effector cells also proved more effective than the monoclonal antibody in eliciting antibody-dependent cellular cytotoxicity against human melanoma target cells in vitro.
Full text
PDF![5407](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71fc/384265/685b71e48efa/pnas00643-0243.png)
![5408](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71fc/384265/7438e6222780/pnas00643-0244.png)
![5409](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71fc/384265/1f50cb949ce8/pnas00643-0245.png)
![5410](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71fc/384265/3c40e7c9dc55/pnas00643-0246.png)
![5411](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71fc/384265/1ff68c9eb63c/pnas00643-0247.png)
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bumol T. F., Reisfeld R. A. Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci U S A. 1982 Feb;79(4):1245–1249. doi: 10.1073/pnas.79.4.1245. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bumol T. F., Wang Q. C., Reisfeld R. A., Kaplan N. O. Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc Natl Acad Sci U S A. 1983 Jan;80(2):529–533. doi: 10.1073/pnas.80.2.529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chee D. O., Boddie A. W., Roth J. A., Holmes E. C., Morton D. L. Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium. Cancer Res. 1976 Apr;36(4):1503–1509. [PubMed] [Google Scholar]
- Ey P. L., Prowse S. J., Jenkin C. R. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry. 1978 Jul;15(7):429–436. doi: 10.1016/0161-5890(78)90070-6. [DOI] [PubMed] [Google Scholar]
- Flexman J. P., Shellam G. R. Target-effector interactions in the rat natural killer cell system. I. The measurement of cytotoxicity at the single cell level. Eur J Immunol. 1982 Jun;12(6):457–463. doi: 10.1002/eji.1830120602. [DOI] [PubMed] [Google Scholar]
- Giuliani F. C., Kaplan N. O. New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse. Cancer Res. 1980 Dec;40(12):4682–4687. [PubMed] [Google Scholar]
- Herberman R. B., Ortaldo J. R. Natural killer cells: their roles in defenses against disease. Science. 1981 Oct 2;214(4516):24–30. doi: 10.1126/science.7025208. [DOI] [PubMed] [Google Scholar]
- Herlyn D., Herlyn M., Steplewski Z., Koprowski H. Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol. 1979 Aug;9(8):657–659. doi: 10.1002/eji.1830090817. [DOI] [PubMed] [Google Scholar]
- Herlyn D., Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci U S A. 1982 Aug;79(15):4761–4765. doi: 10.1073/pnas.79.15.4761. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Imai K., Ng A. K., Glassy M. C., Ferrone S. ADCC of cultured human melanoma cells: analysis with monoclonal antibodies to human melanoma-associated antigens. Scand J Immunol. 1981 Oct;14(4):369–377. doi: 10.1111/j.1365-3083.1981.tb00577.x. [DOI] [PubMed] [Google Scholar]
- Jones J. F., Segal D. M. Antibody-dependent cell-mediated cytolysis (ADCC) with antibody-coated effectors: new methods for enhancing antibody binding and cytolysis. J Immunol. 1980 Aug;125(2):926–933. [PubMed] [Google Scholar]
- Kedar E., Ikejiri B. L., Bonnard G. D., Herberman R. B. A rapid technique for isolation of viable tumor cells from solid tumors: use of the tumor cells for induction and measurement of cell-mediated cytotoxic responses. Eur J Cancer Clin Oncol. 1982 Oct;18(10):991–1000. doi: 10.1016/0277-5379(82)90248-6. [DOI] [PubMed] [Google Scholar]
- Key M., Haskill S. Macrophage-mediated, antibody-dependent destruction of tumor cells in DBA/2 mice: in vitro identification of an in situ mechanism. J Natl Cancer Inst. 1981 Jan;66(1):103–110. [PubMed] [Google Scholar]
- Langlois A. J., Matthews T., Roloson G. J., Thiel H. J., Collins J. J., Bolognesi D. P. Immunologic control of the ascites form of murine adenocarcinoma 755. V. Antibody-directed macrophages mediate tumor cell destruction. J Immunol. 1981 Jun;126(6):2337–2341. [PubMed] [Google Scholar]
- Lieber M., Mazzetta J., Nelson-Rees W., Kaplan M., Todaro G. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer. 1975 May 15;15(5):741–747. doi: 10.1002/ijc.2910150505. [DOI] [PubMed] [Google Scholar]
- Miller R. A., Maloney D. G., Warnke R., Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982 Mar 4;306(9):517–522. doi: 10.1056/NEJM198203043060906. [DOI] [PubMed] [Google Scholar]
- Morgan A. C., Jr, Galloway D. R., Reisfeld R. A. Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma. 1981;1(1):27–36. doi: 10.1089/hyb.1.1981.1.27. [DOI] [PubMed] [Google Scholar]
- Morton D. L., Malmgren R. A., Holmes E. C., Ketcham A. S. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery. 1968 Jul;64(1):233–240. [PubMed] [Google Scholar]
- Ritz J., Schlossman S. F. Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood. 1982 Jan;59(1):1–11. [PubMed] [Google Scholar]
- Rossen R. D., Crane M. M., Morgan A. C., Giannini E. H., Giovanella B. C., Stehlin J. S., Twomey J. J., Hersh E. M. Circulating immune complexes and tumor cell cytotoxins as prognostic indicators in malignant melanoma: a prospective study of 53 patients. Cancer Res. 1983 Jan;43(1):422–429. [PubMed] [Google Scholar]
- Sears H. F., Atkinson B., Mattis J., Ernst C., Herlyn D., Steplewski Z., Häyry P., Koprowski H. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet. 1982 Apr 3;1(8275):762–765. doi: 10.1016/s0140-6736(82)91811-6. [DOI] [PubMed] [Google Scholar]
- Simone C. B. Directed effector cells selectively lyse human tumour cells. Nature. 1982 May 20;297(5863):234–236. doi: 10.1038/297234a0. [DOI] [PubMed] [Google Scholar]
- Stutman O., Cuttito M. J. Normal levels of natural cytotoxic cells against solid tumours in NK-deficient beige mice. Nature. 1981 Mar 19;290(5803):254–257. doi: 10.1038/290254a0. [DOI] [PubMed] [Google Scholar]